Therapeutic options in patients with lymphoma and severe liver dysfunction.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D005260:Female; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008099:Liver / Q000503:physiopathology*; D008107:Liver Diseases / Q000150:complications*; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D016399:Lymphoma, T-Cell / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use*; D008875:Middle Aged; D012189:Retrospective Studies; D000069283:Rituximab
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D008466:Mechlorethamine; D000469:Alkaline Phosphatase; D001663:Bilirubin